Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...